Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01221272
First received: October 13, 2010
Last updated: August 21, 2014
Last verified: August 2014

October 13, 2010
August 21, 2014
September 2010
September 2012   (final data collection date for primary outcome measure)
  • Exercise-induced Perfusion Defect Size (PDS) Following Ranolazine and Placebo Treatment [ Time Frame: Up to 33 days ] [ Designated as safety issue: No ]
    PDS is the amount (percent) of the myocardium with decreased blood flow. A lower percentage means more of the myocardium is receiving blood flow. Measurements were obtained by gated single photon emission computed tomography (SPECT) imaging following exercise at the end of the ranolazine and placebo treatment periods.
  • Exercise-induced Total Perfusion Deficit (TPD) Following Ranolazine and Placebo Treatment [ Time Frame: Up to 33 days ] [ Designated as safety issue: No ]
    TPD is a score that measures the overall impact of a region of decreased myocardial blood flow, incorporating both the amount and severity of the decreased flow. TPD is measured on a scale of 0-100, with higher scores being worse and lower scores being better. Measurements were obtained by SPECT imaging following exercise at the end of the ranolazine and placebo treatment periods.
Effect of ranolazine (versus placebo) on exercise-induced reversible PDS [ Time Frame: 30 days. Subjects may be treated for up to 34 days due to visit windows. ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01221272 on ClinicalTrials.gov Archive Site
  • Perfusion Defect Severity at Baseline, End of Period 1, and End of Period 2 [ Time Frame: Up to 33 days ] [ Designated as safety issue: No ]
    Perfusion defect severity was assessed for each participant as the percentage of the 17 myocardium segments with a relative perfusion defect score of 3 or 4 on a 0-4 scale. Segment scores are: 0 = normal perfusion; 1 = mild reduction in counts-not definitely abnormal; 2 = moderate reduction in counts-definitely abnormal; 3 = severe reduction in counts; 4 = absent uptake (lower scores correspond to less severity and higher scores correspond to increased severity). A lower percentage means fewer segments have severely reduced blood flow. Measurements were obtained by SPECT imaging following exercise at baseline and at the end of Periods 1 and 2.
  • Exercise-induced Reversible Perfusion Defect Size (PDS) at Baseline, End of Period 1, and End of Period 2 [ Time Frame: Up to 33 days ] [ Designated as safety issue: No ]
    Exercise-induced reversible PDS was derived as the exercise PDS at baseline and at the end of Periods 1 and 2 minus the resting PDS at baseline. A lower percentage means more of the myocardium is receiving blood flow. Measurements were obtained by SPECT imaging at baseline both at rest and following exercise and following exercise at the end of Periods 1 and 2.
  • Exercise-induced Reversible Total Perfusion Deficit (TPD) at Baseline, End of Period 1, and End of Period 2 [ Time Frame: Up to 33 days ] [ Designated as safety issue: No ]
    Exercise-induced reversible TPD was derived as the exercise TPD at baseline and at the end of Periods 1 and 2 minus the resting TPD at baseline. TPD is measured on a scale of 0-100, with higher scores being worse and lower scores being better. Measurements were obtained by SPECT imaging at baseline both at rest and following exercise and following exercise at the end of Periods 1 and 2.
Effect of ranolazine (versus placebo) on SPECT MPI variables [ Time Frame: 30 days. Subjects may be treated for up to 34 days due to visit windows. ] [ Designated as safety issue: Yes ]

Effect of ranolazine (versus placebo) on the following SPECT MPI variables:

  1. Total exercise-induced perfusion defect size and severity
  2. Summed difference score (SDS), summed stress score (SSS), and number of reversible segments using a 17-segment model
Not Provided
Not Provided
 
Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

This study enrolled participants with documented exercise-induced myocardial ischemia in order to evaluate whether ranolazine, when taken prior to exercise, can improve blood flow to the heart (myocardial perfusion), as assessed by exercise-induced myocardial perfusion defect size (PDS) and total perfusion deficit (TPD), using gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI).

This was a 2-period crossover study. The last dose of each period must have been taken 3-4 hours prior to conduct of the exercise SPECT MPI. After the research exercise SPECT MPI was performed at the end of Period 1, participants discontinued the treatment they were randomized to for that period and began the other treatment in Period 2.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Myocardial Perfusion Imaging
  • Myocardial Ischemia
  • Drug: Ranolazine
    • One 500 mg tablet in the evening on Day 1 of the period
    • One 500 mg tablet, twice daily on Days 2-3 of the period
    • Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)
    Other Name: Ranexa®
  • Drug: Placebo to match ranolazine
    Placebo to match ranolazine administered in the same form and frequency as the active drug.
  • Procedure: SPECT MPI
    Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.
  • Behavioral: Exercise
    Treadmill stress test
  • Experimental: Ranolazine/Placebo
    Participants received ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
    Interventions:
    • Drug: Ranolazine
    • Drug: Placebo to match ranolazine
    • Procedure: SPECT MPI
    • Behavioral: Exercise
  • Experimental: Placebo/Ranolazine
    Participants received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
    Interventions:
    • Drug: Ranolazine
    • Drug: Placebo to match ranolazine
    • Procedure: SPECT MPI
    • Behavioral: Exercise
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
81
September 2012
September 2012   (final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • Exercise SPECT MPI study (stress and rest) showing at least 10% reversible myocardial ischemia (as confirmed by the core nuclear laboratory using Corridor4DM imaging software) performed not more than 12 weeks prior to screening, OR
  • Exercise SPECT MPI study (stress and rest) conducted during screening (after consultation with the Medical Monitor and after informed consent was obtained) showing at least 10% reversible myocardial ischemia (as confirmed by the core nuclear laboratory)
  • Stable antianginal medical therapy (excluding short-acting nitroglycerin)

Key Exclusion Criteria:

  • Left bundle branch block
  • Automated implantable defibrillator and/or pacemaker (selected subjects with permanent pacemakers who had an intact sinus mechanism may have been included following consultation with the Medical Monitor)
  • Intervening coronary revascularization between the time of qualifying exercise SPECT MPI study and randomization
  • Acute myocardial infarction (MI) within 60 days prior to screening or at any time after the qualifying exercise SPECT MPI study, or MI undergoing staged intervention during a subject's participation in the trial
  • Unstable angina within 30 days prior to screening, or at any time after the qualifying exercise SPECT MPI study
  • Coronary artery bypass graft surgery within 60 days prior to screening or at any time after the qualifying exercise SPECT MPI study, or percutaneous coronary intervention within 30 days prior to screening or at any time after the qualifying exercise SPECT MPI study
  • Anticipated coronary revascularization during the trial period
  • Cerebrovascular attack or transient ischemic attack within 90 days prior to screening
  • History of serious arrhythmias
  • Current atrial fibrillation or atrial flutter
  • QTc interval > 500 milliseconds
  • Diagnosed as having New York Heart Association Class III or IV heart failure
  • Inability to exercise or exercise limitation due to other comorbidities that may have interfered with ability to perform required exercise SPECT MPI study
  • Body mass index greater than or equal to 38 kg/m^2 (may have been up to 40 kg/m^2 after consultation with the Medical Monitor)
  • Any absolute contraindications to exercise stress testing
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada,   Czech Republic,   Finland,   Israel,   Italy,   Singapore,   United Kingdom
 
NCT01221272
GS-US-259-0103
No
Gilead Sciences
Gilead Sciences
Not Provided
Study Director: Patrick Yue, MD Gilead Sciences
Gilead Sciences
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP